Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various asp… Read more
Bio-Techne Corp (TECH) - Net Assets
Latest net assets as of December 2025: $2.01 Billion USD
Based on the latest financial reports, Bio-Techne Corp (TECH) has net assets worth $2.01 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.52 Billion) and total liabilities ($511.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.01 Billion |
| % of Total Assets | 79.72% |
| Annual Growth Rate | 19.55% |
| 5-Year Change | 22.12% |
| 10-Year Change | 118.22% |
| Growth Volatility | 18.47 |
Bio-Techne Corp - Net Assets Trend (1989–2025)
This chart illustrates how Bio-Techne Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bio-Techne Corp (1989–2025)
The table below shows the annual net assets of Bio-Techne Corp from 1989 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $1.92 Billion | -7.25% |
| 2024-06-30 | $2.07 Billion | +5.20% |
| 2023-06-30 | $1.97 Billion | +15.61% |
| 2022-06-30 | $1.70 Billion | +8.26% |
| 2021-06-30 | $1.57 Billion | +13.76% |
| 2020-06-30 | $1.38 Billion | +18.50% |
| 2019-06-30 | $1.17 Billion | +8.01% |
| 2018-06-30 | $1.08 Billion | +13.50% |
| 2017-06-30 | $950.83 Million | +8.14% |
| 2016-06-30 | $879.28 Million | +3.82% |
| 2015-06-30 | $846.93 Million | +6.50% |
| 2014-06-30 | $795.26 Million | +7.83% |
| 2013-06-30 | $737.54 Million | +9.36% |
| 2012-06-30 | $674.44 Million | +15.07% |
| 2011-06-30 | $586.12 Million | +16.81% |
| 2010-06-30 | $501.79 Million | +9.93% |
| 2009-06-30 | $456.48 Million | -6.29% |
| 2008-06-30 | $487.13 Million | +11.31% |
| 2007-06-30 | $437.65 Million | +28.59% |
| 2006-06-30 | $340.35 Million | +27.06% |
| 2005-06-30 | $267.87 Million | -9.94% |
| 2004-06-30 | $297.43 Million | +25.70% |
| 2003-06-30 | $236.62 Million | +14.58% |
| 2002-06-30 | $206.52 Million | +16.24% |
| 2001-06-30 | $177.66 Million | +25.87% |
| 2000-06-30 | $141.15 Million | +45.81% |
| 1999-06-30 | $96.80 Million | +51.72% |
| 1998-06-30 | $63.80 Million | +32.64% |
| 1997-06-30 | $48.10 Million | +23.65% |
| 1996-06-30 | $38.90 Million | +31.86% |
| 1995-06-30 | $29.50 Million | +28.26% |
| 1994-06-30 | $23.00 Million | +29.21% |
| 1993-06-30 | $17.80 Million | +58.93% |
| 1992-06-30 | $11.20 Million | +77.78% |
| 1991-06-30 | $6.30 Million | +36.96% |
| 1990-06-30 | $4.60 Million | +48.39% |
| 1989-06-30 | $3.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bio-Techne Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 118349.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.07 Billion | 55.56% |
| Common Stock | $1.55 Million | 0.08% |
| Other Comprehensive Income | $-59.88 Million | -3.12% |
| Other Components | $911.09 Million | 47.48% |
| Total Equity | $1.92 Billion | 100.00% |
Bio-Techne Corp Competitors by Market Cap
The table below lists competitors of Bio-Techne Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Invesco Plc
NYSE:IVZ
|
$7.90 Billion |
|
Eastman Chemical Company
NYSE:EMN
|
$7.90 Billion |
|
Fortis Inc. CUM RD 5Y SR G
PINK:FTRSF
|
$7.90 Billion |
|
Trelleborg AB (publ)
PINK:TBABF
|
$7.91 Billion |
|
LS Electric
KO:010120
|
$7.89 Billion |
|
New Gold Inc
NYSE MKT:NGD
|
$7.88 Billion |
|
Boston Properties Inc
NYSE:BXP
|
$7.87 Billion |
|
HELVETIA BA.HL.NA SF 0,02
F:HVXA
|
$7.86 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bio-Techne Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,068,850,000 to 1,918,808,000, a change of -150,042,000 (-7.3%).
- Net income of 73,400,000 contributed positively to equity growth.
- Dividend payments of 50,391,000 reduced retained earnings.
- Share repurchases of 275,731,000 reduced equity.
- Other comprehensive income increased equity by 18,436,000.
- Other factors increased equity by 84,244,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $73.40 Million | +3.83% |
| Dividends Paid | $50.39 Million | -2.63% |
| Share Repurchases | $275.73 Million | -14.37% |
| Other Comprehensive Income | $18.44 Million | +0.96% |
| Other Changes | $84.24 Million | +4.39% |
| Total Change | $- | -7.25% |
Book Value vs Market Value Analysis
This analysis compares Bio-Techne Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.25x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 2077.71x to 4.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1989-06-30 | $0.02 | $51.06 | x |
| 1990-06-30 | $0.03 | $51.06 | x |
| 1991-06-30 | $0.05 | $51.06 | x |
| 1992-06-30 | $0.08 | $51.06 | x |
| 1993-06-30 | $0.12 | $51.06 | x |
| 1994-06-30 | $0.16 | $51.06 | x |
| 1995-06-30 | $0.19 | $51.06 | x |
| 1996-06-30 | $0.25 | $51.06 | x |
| 1997-06-30 | $0.31 | $51.06 | x |
| 1998-06-30 | $0.41 | $51.06 | x |
| 1999-06-30 | $0.58 | $51.06 | x |
| 2000-06-30 | $0.84 | $51.06 | x |
| 2001-06-30 | $1.04 | $51.06 | x |
| 2002-06-30 | $1.21 | $51.06 | x |
| 2003-06-30 | $1.41 | $51.06 | x |
| 2004-06-30 | $1.78 | $51.06 | x |
| 2005-06-30 | $1.64 | $51.06 | x |
| 2006-06-30 | $2.15 | $51.06 | x |
| 2007-06-30 | $2.77 | $51.06 | x |
| 2008-06-30 | $3.10 | $51.06 | x |
| 2009-06-30 | $3.01 | $51.06 | x |
| 2010-06-30 | $3.36 | $51.06 | x |
| 2011-06-30 | $3.94 | $51.06 | x |
| 2012-06-30 | $4.56 | $51.06 | x |
| 2013-06-30 | $5.00 | $51.06 | x |
| 2014-06-30 | $5.37 | $51.06 | x |
| 2015-06-30 | $5.69 | $51.06 | x |
| 2016-06-30 | $5.89 | $51.06 | x |
| 2017-06-30 | $6.34 | $51.06 | x |
| 2018-06-30 | $7.09 | $51.06 | x |
| 2019-06-30 | $7.49 | $51.06 | x |
| 2020-06-30 | $8.76 | $51.06 | x |
| 2021-06-30 | $9.65 | $51.06 | x |
| 2022-06-30 | $10.37 | $51.06 | x |
| 2023-06-30 | $12.15 | $51.06 | x |
| 2024-06-30 | $12.87 | $51.06 | x |
| 2025-06-30 | $12.01 | $51.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bio-Techne Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.02%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.33x
- Recent ROE (3.83%) is below the historical average (17.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1989 | 12.90% | 3.20% | 2.05x | 1.97x | $90.00K |
| 1990 | 21.74% | 6.37% | 1.96x | 1.74x | $540.00K |
| 1991 | 25.40% | 8.29% | 2.01x | 1.52x | $970.00K |
| 1992 | 17.86% | 8.97% | 1.42x | 1.40x | $880.00K |
| 1993 | 24.72% | 15.33% | 1.41x | 1.15x | $2.62 Million |
| 1994 | 22.17% | 12.66% | 1.50x | 1.17x | $2.80 Million |
| 1995 | 22.71% | 14.05% | 1.40x | 1.16x | $3.75 Million |
| 1996 | 22.11% | 15.75% | 1.23x | 1.14x | $4.71 Million |
| 1997 | 22.66% | 17.90% | 1.13x | 1.12x | $6.09 Million |
| 1998 | 23.82% | 22.59% | 0.92x | 1.14x | $8.82 Million |
| 1999 | 17.25% | 18.37% | 0.73x | 1.28x | $7.02 Million |
| 2000 | 18.83% | 25.60% | 0.58x | 1.28x | $12.47 Million |
| 2001 | 19.16% | 29.51% | 0.54x | 1.21x | $16.28 Million |
| 2002 | 13.14% | 20.73% | 0.55x | 1.15x | $6.48 Million |
| 2003 | 19.19% | 31.31% | 0.55x | 1.11x | $21.73 Million |
| 2004 | 17.80% | 32.82% | 0.50x | 1.09x | $23.19 Million |
| 2005 | 24.69% | 37.02% | 0.61x | 1.10x | $39.35 Million |
| 2006 | 21.55% | 36.20% | 0.55x | 1.09x | $39.32 Million |
| 2007 | 19.45% | 38.08% | 0.49x | 1.04x | $41.35 Million |
| 2008 | 21.26% | 40.23% | 0.51x | 1.04x | $54.84 Million |
| 2009 | 23.06% | 39.87% | 0.56x | 1.03x | $59.59 Million |
| 2010 | 21.88% | 40.80% | 0.52x | 1.03x | $59.60 Million |
| 2011 | 19.16% | 38.73% | 0.47x | 1.05x | $53.69 Million |
| 2012 | 16.66% | 35.71% | 0.44x | 1.07x | $44.89 Million |
| 2013 | 15.26% | 36.24% | 0.40x | 1.05x | $38.81 Million |
| 2014 | 13.95% | 31.01% | 0.41x | 1.08x | $31.42 Million |
| 2015 | 12.72% | 23.82% | 0.43x | 1.26x | $23.04 Million |
| 2016 | 11.88% | 20.94% | 0.44x | 1.28x | $16.55 Million |
| 2017 | 8.13% | 13.73% | 0.36x | 1.64x | $-17.80 Million |
| 2018 | 11.62% | 19.49% | 0.40x | 1.48x | $17.44 Million |
| 2019 | 8.24% | 13.46% | 0.38x | 1.62x | $-20.49 Million |
| 2020 | 16.60% | 31.04% | 0.36x | 1.47x | $91.18 Million |
| 2021 | 8.98% | 15.08% | 0.41x | 1.45x | $-15.89 Million |
| 2022 | 15.99% | 24.61% | 0.48x | 1.35x | $101.87 Million |
| 2023 | 14.51% | 25.10% | 0.43x | 1.34x | $88.61 Million |
| 2024 | 8.13% | 14.50% | 0.43x | 1.31x | $-38.78 Million |
| 2025 | 3.83% | 6.02% | 0.48x | 1.33x | $-118.48 Million |
Industry Comparison
This section compares Bio-Techne Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bio-Techne Corp (TECH) | $2.01 Billion | 12.90% | 0.25x | $7.89 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |